CATABASIS PHARMACEUTICALS IN's ticker is and the CUSIP is 14875P206. A total of 59 filers reported holding CATABASIS PHARMACEUTICALS IN in Q2 2021. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $974,000 | +698.4% | 461,609 | +708.5% | 0.00% | – |
| Q4 2020 | $122,000 | +56.4% | 57,097 | +354.1% | 0.00% | – |
| Q3 2020 | $78,000 | -27.1% | 12,574 | -24.4% | 0.00% | – |
| Q2 2020 | $107,000 | -37.1% | 16,624 | -21.3% | 0.00% | – |
| Q2 2019 | $170,000 | -70.3% | 21,118 | -70.8% | 0.00% | -100.0% |
| Q1 2019 | $573,000 | – | 72,324 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 4,092,166 | $8,634,000 | 3.55% |
| COMMODORE CAPITAL LP | 1,617,000 | $3,412,000 | 1.19% |
| ACUTA CAPITAL PARTNERS, LLC | 1,173,674 | $2,476,000 | 0.99% |
| VR Adviser, LLC | 3,234,000 | $6,824,000 | 0.83% |
| Logos Global Management LP | 3,190,000 | $6,731,000 | 0.57% |
| Cormorant Asset Management, LP | 3,550,000 | $7,490,000 | 0.25% |
| Soleus Capital Management, L.P. | 775,000 | $1,635,000 | 0.25% |
| Perceptive Advisors | 15,374,370 | $32,438,000 | 0.21% |
| RA Capital Management | 5,947,861 | $12,550,000 | 0.20% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 188,777 | $398,000 | 0.18% |